KRCA-0008 manufacturers
- KRCA-0008
-
- $39.00 / 5mg
-
2024-11-19
- CAS:1472795-20-2
- Min. Order:
- Purity: 98.43%
- Supply Ability: 10g
|
| | KRCA-0008 Basic information |
| Product Name: | KRCA-0008 | | Synonyms: | KRCA-0008;KRCA-008;1,1'-[(5-Chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bisethanone;CS-1715;Ethanone, 1,1'-[(5-chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bis-;KRCA-0008 >=98% (HPLC);GABA NG;GABANG | | CAS: | 1472795-20-2 | | MF: | C30H37ClN8O4 | | MW: | 609.12 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1472795-20-2.mol |  |
| | KRCA-0008 Chemical Properties |
| Boiling point | 870.2±75.0 °C(Predicted) | | density | 1.332±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | H2O : < 0.1 mg/mL (insoluble) | | form | Powder | | pka | 3.99±0.50(Predicted) | | color | White to gray |
| | KRCA-0008 Usage And Synthesis |
| Uses | KRCA 0008 is a potent and selective ALK inhibitors for anticancer treatment. | | in vivo | KRCA-0008 (25 and 50 mg/kg; p.o. twice a day for two weeks) suppresses tumor growth in an ALK-positive Karpas-299 xenograft model[2]. | Animal Model: | NOD/SCID mice with Karpas-299 xenografts[2] | | Dosage: | 25 and 50 mg/kg | | Administration: | Oral gavage; 25 and 50 mg/kg twice a day; for two weeks | | Result: | Significantly inhibited tumor growth by inhibiting NPM-ALK phosphorylation without showing overt signs of toxicity or significant compound-related body weight loss. |
| | storage | Store at -20°C |
| | KRCA-0008 Preparation Products And Raw materials |
|